M Oliveira1, C Saura2, P Nuciforo3, I Calvo4, J Andersen5, J L Passos-Coelho6, M Gil Gil7, B Bermejo8, D A Patt9, E Ciruelos10, L de la Peña11, N Xu12, M Wongchenko13, Z Shi13, S M Singel12, S J Isakoff14. 1. Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona; SOLTI Breast Cancer Research Group, Barcelona. Electronic address: moliveira@vhio.net. 2. Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona; SOLTI Breast Cancer Research Group, Barcelona. 3. Molecular Oncology Group, VHIO, Barcelona. 4. Breast Cancer Unit, Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain. 5. Medical Oncology and Hematology, Compass Oncology and US Oncology, Portland, USA. 6. Oncology Department, Hospital Beatriz Angelo, Loures, Portugal. 7. SOLTI Breast Cancer Research Group, Barcelona; Medical Oncology Service, Institut Català d'Oncologia, L'Hospitalet, Barcelona; Institut d'Investigació Biomédica de Bellvitge (IDIBELL), Barcelona. 8. Hospital Clinico Universitario, Valencia, Spain. 9. Texas Oncology Cancer Center, US Oncology, Austin, USA. 10. SOLTI Breast Cancer Research Group, Barcelona; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain. 11. SOLTI Breast Cancer Research Group, Barcelona. 12. Product Development Oncology, Genentech Inc., South San Francisco. 13. Oncology Biomarker Department, Genentech Inc., South San Francisco. 14. Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, USA.
Abstract
BACKGROUND: This hypothesis-generating trial evaluated neoadjuvant ipatasertib-paclitaxel for early triple-negative breast cancer (TNBC). PATIENTS AND METHODS: In this randomized phase II trial, patients with early TNBC (T ≥ 1.5 cm, N0-2) were randomized 1 : 1 to receive weekly paclitaxel 80 mg/m2 with ipatasertib 400 mg or placebo (days 1-21 every 28 days) for 12 weeks before surgery. Co-primary end points were pathologic complete response (pCR) rate (ypT0/TisN0) in the intention-to-treat (ITT) and immunohistochemistry phosphatase and tensin homolog (PTEN)-low populations. Secondary end points included pCR rate in patients with PIK3CA/AKT1/PTEN-altered tumors and pre-surgery response rates by magnetic resonance imaging (MRI). RESULTS:pCR rates with ipatasertib versus placebo were 17% versus 13%, respectively, in the ITT population (N = 151), 16% versus 13% in the immunohistochemistry PTEN-low population (N = 35), and 18% versus 12% in the PIK3CA/AKT1/PTEN-altered subgroup (N = 62). Rates of overall and complete response (CR) by MRI favored ipatasertib in all three populations (CR rate 39% versus 9% in the PIK3CA/AKT1/PTEN-altered subgroup). Ipatasertib was associated with more grade ≥3 adverse events (32% versus 16% with placebo), especially diarrhea (17% versus 1%). Higher cycle 1 day 8 (C1D8) immune score was significantly associated with better response only in placebo-treated patients. All ipatasertib-treated patients with low immune scores and a CR had PIK3CA/AKT1/PTEN-altered tumors. CONCLUSIONS: Adding ipatasertib to 12 weeks of paclitaxel for early TNBC did not clinically or statistically significantly increase pCR rate, although overall response rate by MRI was numerically higher with ipatasertib. The antitumor effect of ipatasertib was most pronounced in biomarker-selected patients. Safety was consistent with prior experience of ipatasertib-paclitaxel. A T-cell-rich environment at C1D8 had a stronger association with improved outcomes in paclitaxel-treated patients than seen for baseline tumor-infiltrating lymphocytes. This dependency may be overcome with the addition of AKT inhibition, especially in patients with PIK3CA/AKT1/PTEN-altered tumors. CLINICALTRIALS.GOV: NCT02301988.
RCT Entities:
BACKGROUND: This hypothesis-generating trial evaluated neoadjuvant ipatasertib-paclitaxel for early triple-negative breast cancer (TNBC). PATIENTS AND METHODS: In this randomized phase II trial, patients with early TNBC (T ≥ 1.5 cm, N0-2) were randomized 1 : 1 to receive weekly paclitaxel 80 mg/m2 with ipatasertib 400 mg or placebo (days 1-21 every 28 days) for 12 weeks before surgery. Co-primary end points were pathologic complete response (pCR) rate (ypT0/TisN0) in the intention-to-treat (ITT) and immunohistochemistry phosphatase and tensin homolog (PTEN)-low populations. Secondary end points included pCR rate in patients with PIK3CA/AKT1/PTEN-altered tumors and pre-surgery response rates by magnetic resonance imaging (MRI). RESULTS: pCR rates with ipatasertib versus placebo were 17% versus 13%, respectively, in the ITT population (N = 151), 16% versus 13% in the immunohistochemistry PTEN-low population (N = 35), and 18% versus 12% in the PIK3CA/AKT1/PTEN-altered subgroup (N = 62). Rates of overall and complete response (CR) by MRI favored ipatasertib in all three populations (CR rate 39% versus 9% in the PIK3CA/AKT1/PTEN-altered subgroup). Ipatasertib was associated with more grade ≥3 adverse events (32% versus 16% with placebo), especially diarrhea (17% versus 1%). Higher cycle 1 day 8 (C1D8) immune score was significantly associated with better response only in placebo-treated patients. All ipatasertib-treated patients with low immune scores and a CR had PIK3CA/AKT1/PTEN-altered tumors. CONCLUSIONS: Adding ipatasertib to 12 weeks of paclitaxel for early TNBC did not clinically or statistically significantly increase pCR rate, although overall response rate by MRI was numerically higher with ipatasertib. The antitumor effect of ipatasertib was most pronounced in biomarker-selected patients. Safety was consistent with prior experience of ipatasertib-paclitaxel. A T-cell-rich environment at C1D8 had a stronger association with improved outcomes in paclitaxel-treated patients than seen for baseline tumor-infiltrating lymphocytes. This dependency may be overcome with the addition of AKT inhibition, especially in patients with PIK3CA/AKT1/PTEN-altered tumors. CLINICALTRIALS.GOV: NCT02301988.
Authors: Inchul You; Emily C Erickson; Katherine A Donovan; Nicholas A Eleuteri; Eric S Fischer; Nathanael S Gray; Alex Toker Journal: Cell Chem Biol Date: 2019-12-16 Impact factor: 8.116
Authors: A Jo Chien; Debasish Tripathy; Kathy S Albain; W Fraser Symmans; Hope S Rugo; Michelle E Melisko; Anne M Wallace; Richard Schwab; Teresa Helsten; Andres Forero-Torres; Erica Stringer-Reasor; Erin D Ellis; Henry G Kaplan; Rita Nanda; Nora Jaskowiak; Rashmi Murthy; Constantine Godellas; Judy C Boughey; Anthony D Elias; Barbara B Haley; Kathleen Kemmer; Claudine Isaacs; Amy S Clark; Julie E Lang; Janice Lu; Larissa Korde; Kirsten K Edmiston; Donald W Northfelt; Rebecca K Viscusi; Douglas Yee; Jane Perlmutter; Nola M Hylton; Laura J Van't Veer; Angela DeMichele; Amy Wilson; Garry Peterson; Meredith B Buxton; Melissa Paoloni; Julia Clennell; Scott Berry; Jeffrey B Matthews; Katherine Steeg; Ruby Singhrao; Gillian L Hirst; Ashish Sanil; Christina Yau; Smita M Asare; Donald A Berry; Laura J Esserman Journal: J Clin Oncol Date: 2019-02-07 Impact factor: 44.544
Authors: Albert Gris-Oliver; Marta Palafox; Mafalda Oliveira; Violeta Serra; Laia Monserrat; Fara Brasó-Maristany; Andreu Òdena; Mònica Sánchez-Guixé; Yasir H Ibrahim; Guillermo Villacampa; Judit Grueso; Mireia Parés; Marta Guzmán; Olga Rodríguez; Alejandra Bruna; Caroline S Hirst; Alan Barnicle; Elza C de Bruin; Avinash Reddy; Gaia Schiavon; Joaquín Arribas; Gordon B Mills; Carlos Caldas; Rodrigo Dienstmann; Aleix Prat; Paolo Nuciforo; Pedram Razavi; Maurizio Scaltriti; Nicholas C Turner; Cristina Saura; Barry R Davies Journal: Clin Cancer Res Date: 2020-03-27 Impact factor: 12.531
Authors: Javier Cortés; Violeta Serra; Albert Gris-Oliver; Yasir H Ibrahim; Martín A Rivas; Celina García-García; Mònica Sánchez-Guixé; Fiorella Ruiz-Pace; Cristina Viaplana; José M Pérez-García; Antonio Llombart-Cussac; Judit Grueso; Mireia Parés; Marta Guzmán; Olga Rodríguez; Pilar Anton; Patricia Cozar; Maria Teresa Calvo; Alejandra Bruna; Joaquín Arribas; Carlos Caldas; Rodrigo Dienstmann; Paolo Nuciforo; Mafalda Oliveira Journal: Br J Cancer Date: 2021-03-15 Impact factor: 7.640